Table 2.
Summary of evaluable patient treatment outcomes on study
| Patient | Treatment Duration (courses) | Best Reduction in Target Left/Right Tumor Volume (% baseline volume) | Progression of Target Left/Right Tumor Volume (% baseline volume) | Best Change in WRS in Target Left/Right ear (absolute score in %; difference from baseline) | Best Change in PTA (dB) for Target Tumor in Left/Right (absolute PTA; difference from baseline) | Reason for Treatment Discontinuation |
|---|---|---|---|---|---|---|
| 1 | 21 | −13.73 | NA | NA | NA | Patient preference |
| 2 | 3 | No reduction | +17.57 | 0 (−4) | 56.25 (+10.00) | R VS growth |
| 3 | 12 | −3.90/−11.48 | +20.78/+19.67 | 100/NA (+16) | 28.75/NA (0) | R and L VS growth |
| 4 | 3 | NA | +10.41 | NA | NA | R VS growth |
| 5 | 15 | −6.25 | NA | 44 (+40) | 51.25 (−3.75) | Patient preference |
| 6 | 21 | −16.57 | NA | 80 (+8) | 48.75 (+10.00) | Progressive hearing loss |
| 7 | 6 | No reduction | +10.89/+16.89 | NA/NA | NA/NA | R VS growth |
| 8 | 6 | No reduction | +21.14 | 100 (+4) | 21.25 (−5.00) | L VS growth |
| 9 | 12 | −23.90/−20.25 | NA/NA | NA/100 (+8) | NA/23.75 (−3.75) | Growth of R VS cystic component |
| 10 | 15 | −19.79 | NA | NA | NA | Delay in wound healing |
| 11 | 9 | −3.33 | NA | 96 (+12) | 31.25 (−2.50) | Progressive hearing loss |
| 12 | 12 | −14.15 | NA | 100 (0) | 3.75 (+1.25) | Completed 12 cycles |
| 13 | 12 | −15.74 | NA | 100 (0) | 10.00 (−2.50) | Completed 12 cycles |
| 14 | 16 | −7.31 | NA | 100 (+4) | 21.25 (0) | Patient preference |
| 15 | 12 | −1.77 | +22.12 | NA | NA | R VS growth |
| 16 | 3 | −3.64/NA | NA/+18.64 | 32/NA (−4) | 63.75/NA (−2.50) | R VS growth |
| 17 | 12 | −5.73/−3.91 | NA/NA | 100/96 (0/+4) | 10.00/40.00 (−1.25/−7.50) | Completed 12 cycles |
Boldface values signify that the value met the clinical definition for response.
Abbreviations: R, right; L, left; VS, vestibular schwannoma; WRS, word recognition score; PTA, pure tone average; NA, not applicable.